|
AU2016269576A1
|
|
Soluble human ST-2 antibodies and assays
|
|
CN110568193A
|
|
test device and method for ST2 cardiac biomarkers
|
|
EP3092488A1
|
|
Methods and systems for determining risk of heart failure
|
|
US2016169879A1
|
|
Test apparatus and methods for ST2 cardiac biomarker
|
|
US2016169882A1
|
|
Test apparatus and methods for ST2 cardiac biomarker
|
|
MX2015002254A
|
|
Multimarker risk stratification.
|
|
CA2882133A1
|
|
Methods for predicting risk of developing hypertension
|
|
WO2013173778A1
|
|
Methods for treating or predicting risk of a ventricular tachyarrhythmia event
|
|
AU2013204182A1
|
|
Soluble human ST-2 antibodies and assays
|
|
AU2013204539A1
|
|
Predicting mortality and detecting severe disease
|
|
WO2013012945A1
|
|
Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
|
|
AU2012202069A1
|
|
Predicting mortality and detecting severe disease
|
|
CN106940375A
|
|
The method for predicting the risk of bad clinical effectiveness
|
|
AU2011203031A1
|
|
Diagnosis of cardiovascular disease
|
|
EP3050901A1
|
|
Soluble human st-2 antibodies and assays
|
|
AU2009236109A1
|
|
Predicting risk of major adverse cardiac events
|
|
EP2995951A1
|
|
Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
|
|
WO2007130962A2
|
|
Diagnosis of cardiovascular disease
|
|
EP2021799A2
|
|
Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
|
|
AU2007244927A1
|
|
Predicting mortality and detecting severe disease
|
